Mirian Starmans‐Kool

Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study

Daniëlle M. Gerlag, M. Safy, Karen I. Maijer et al. · Annals of the Rheumatic Diseases · 2018 · 287 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

Andrew P. Cope, Marianna Jasenecova, Joana C. Vasconcelos et al. · The Lancet · 2024 · 160 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial

Anna Moltó, Clementina López‐Medina, Filip Van den Bosch et al. · Annals of the Rheumatic Diseases · 2021 · 103 citations · Full text

Medicine, Pharmacotherapy, Musculoskeletal Medicine +14

Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open‐Label Randomized Controlled Trial

Marjan Ghiti Moghadam, Harald E. Vonkeman, Peter M. ten Klooster et al. · Arthritis & Rheumatology · 2016 · 91 citations · Full text

Medicine, Immunology, Pharmacotherapy +15

Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial

Laurette van Boheemen, Samina A. Turk, Marian H. van Beers-Tas et al. · RMD Open · 2021 · 72 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +13